Jan 23 (Reuters) - Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd:
* ‍EXPECTS TO RECORD A DECREASE IN NET PROFIT OF GROUP BY APPROXIMATELY 50% FOR FY
* ‍EXPECTS DECREASE IN FY REVENUE OF GROUP BY APPROXIMATELY 20%
* EXPECTED DECREASE IN REVENUE DUE TO DECREASED REVENUE FROM LIBOD BY ABOUT 50% FOR FY ENDED 31 DEC 2017​ Source text for Eikon: Further company coverage:
 